Processing...
Clinical Trials for Small Cell Lung Cancer
Search
Search
There are 445 active trials for advanced/metastatic small cell lung cancer.
Click on a trial to see more information.
445 trials meet filter criteria.
Sort by:
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic ER+ HER2- breast cancer, mCRPC, or NSCLC who have progressed after standard therapies, to receive OP-3136, an oral selective KAT6A/B inhibitor targeting key epigenetic regulators, as monotherapy. Eligible patients must have unresectable disease or no further effective standard treatment options.
ClinicalTrials.gov ID: NCT06784193
TrialFetch AI summary: Adults with unresectable/metastatic solid tumors harboring KRAS G12D and HLA-C*08:02 (e.g., NSCLC, colorectal, pancreatic, endometrial) after ≥1 prior therapy receive lymphodepletion followed by a single infusion of NT-112, an autologous TCR-engineered T-cell therapy targeting KRAS G12D and CRISPR-edited to disrupt TGF-βRII, with IL-2 support. Single-arm dose escalation assessing safety and preliminary efficacy.
ClinicalTrials.gov ID: NCT06218914
TrialFetch AI summary: This trial enrolls adults with unresectable, locally advanced or metastatic solid tumors—including a wide range such as head and neck, lung, bladder, prostate, breast, colorectal, and others—who have progressed on or are intolerant to standard therapies. Patients receive MGC026, a B7-H3-targeted antibody-drug conjugate delivering a topoisomerase I inhibitor (exatecan), with cohorts in both dose escalation and expansion phases.
ClinicalTrials.gov ID: NCT06242470
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic colorectal, pancreatic, gastric/gastroesophageal junction, or lung cancers that have progressed after standard therapy, testing PF-08046050 (SGN-CEACAM5C), an anti-CEACAM5 antibody-drug conjugate linked to a topoisomerase I inhibitor, as monotherapy and in combination with bevacizumab. Eligible patients must have measurable disease and ECOG 0-1.
ClinicalTrials.gov ID: NCT06131840
TrialFetch AI summary: Eligible patients are adults with advanced, folate receptor alpha–expressing solid tumors—including ovarian, endometrial, cervical, non-small cell lung, triple-negative breast, pancreatic, or colorectal cancer—without uncontrolled CNS metastases or significant comorbidities. Treatment involves investigational LY4170156, a topoisomerase I inhibitor antibody-drug conjugate targeting FRα, given as monotherapy or combined with bevacizumab or carboplatin.
ClinicalTrials.gov ID: NCT06400472
TrialFetch AI summary: Eligible patients are adults with advanced or metastatic solid tumors—especially those with CCNE1-amplified ovarian, endometrial, gastric/GEJ, or esophageal adenocarcinoma, small cell lung cancer, triple-negative breast cancer, or HR+ HER2- breast cancer post-CDK4/6 inhibitor—who have exhausted standard therapies, receiving oral NKT3964, a selective CDK2 PROTAC degrader targeting the CDK2/cyclin E pathway.
ClinicalTrials.gov ID: NCT06586957
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors who have progressed after standard therapies to receive DB-1310, a HER3-targeting antibody-drug conjugate with a topoisomerase I inhibitor payload, as monotherapy or in combination with trastuzumab (HER2+ breast cancer) or osimertinib (EGFR-mutant NSCLC). Key eligibility includes measurable disease, ECOG 0-1, and no prior HER3-ADC or topoisomerase I inhibitor exposure.
ClinicalTrials.gov ID: NCT05785741
TrialFetch AI summary: Eligible patients are adults with metastatic solid tumors (ECOG 0-1, measurable disease, adequate organ function) who will receive MDX2001, a tetraspecific antibody that engages T cells via CD3/CD28 and targets TROP2 and c-MET on tumor cells. The trial excludes individuals with major cardiac disease, active brain metastases, uncontrolled infections, or unresolved toxicities.
ClinicalTrials.gov ID: NCT06239194
TrialFetch AI summary: Adults with advanced or metastatic solid tumors harboring specific KRAS mutations (G12C, G12D, G12V, G12A, G12S, or G13D) are eligible for treatment with LY4066434, a highly selective small molecule pan-KRAS inhibitor, given as monotherapy or in combination with standard chemotherapy or immunotherapy regimens. Active CNS metastases and significant unresolved toxicities are exclusion criteria.
ClinicalTrials.gov ID: NCT06607185
TrialFetch AI summary: Adults with unresectable, advanced, or metastatic solid tumors (including NSCLC, colorectal, HNSCC, pancreatic, ovarian, or breast cancer) that are both HLA-A*02:01 positive and harbor the TP53 R175H mutation, and who have progressed on prior therapy, may receive NT-175, an autologous T cell product genetically engineered with a TCR targeting TP53 R175H and rendered resistant to TGF-β mediated immunosuppression. Treatment includes leukapheresis, lymphodepletion (fludarabine/cyclophosphamide), NT-175 infusion, and short-course subcutaneous IL-2.
ClinicalTrials.gov ID: NCT05877599